Postoperative Nausea and Vomiting
Conditions
Keywords
Nausea and Vomiting
Brief summary
This study is looking at whether the addition of Aprepitant (Emend), an antiemetic, will provide added efficacy if added to 2 drugs that are already used as a standard of care for post-operative nausea and vomiting and post-discharge nausea and vomiting.
Detailed description
This study is looking at whether the addition of a fairly new drug for the treatment of post-operative nausea and vomiting (PONV) and post-discharge nausea and vomiting (PDNV) will provide added efficacy if added to 2 drugs that are already used as a standard of care for PONV and PDNV. The patients that will be looked at will be deemed at higher risk for PONV and PDNV based on the procedure they are having done and/or on patient risk factors.
Interventions
DRUGaprepitant
Emend 40mg by mouth 30 minutes before procedure x 1
Sponsors
University of Nebraska
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients with at least 2 of the common risk factors for PONV/PDNV; patients having a procedure deemed at high risk for PONV/PDNV
Exclusion criteria
* patients under 19 years of age; pregnant and breast-feeding patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| EMEND Added to Standard Treatment of Post-operative and Post-Discharge Nausea and Vomiting | 1 year | To see if by adding EMEND to a standard treatment regimen for PONV/PDNV, added efficacy will be obtained. To see if there is more efficacy for PONV vs. PDNV by adding EMEND to the treatment regimen |
Outcome results
None listed